Advertisement
INSM vs LLY
Which Stock Would AI Choose? Insmed Incorporated (INSM) vs. Eli Lilly and Company (LLY) Stock Comparison
Key Takeaways
- INSM, a biotech focused on rare respiratory diseases, reported strong 2025 revenue growth to $606 million driven by ARIKAYCE and new launch BRINSUPRI, with 2026 guidance projecting at least $1.45 billion.
- LLY, a large-cap pharma leader in diabetes and obesity, achieved $65 billion in 2025 revenue, guiding $80-83 billion for 2026 amid robust Mounjaro and Zepbound demand.
- Year-to-date, both stocks have faced pressure, with INSM down ~20% and LLY ~8%, but INSM delivered superior 1-year returns of ~86% versus LLY's ~24%.
- INSM trades at a $30 billion market cap with high growth potential but elevated risk (beta 1.17), while LLY's $880 billion cap offers stability (beta 0.43) and profitability (P/E 43).
- Analysts rate both as Strong Buy, with INSM targets implying ~35% upside and LLY ~19%.
- Recent sentiment for INSM boosted by product launches; LLY pressured by competition and pricing in GLP-1 market.
Introduction
This stock comparison examines INSM and LLY, two healthcare players navigating distinct paths in biotechnology and pharmaceuticals. INSM targets niche rare diseases with high-growth therapies, appealing to traders seeking momentum in biotech launches. LLY dominates broader markets like obesity and diabetes with blockbuster drugs, attracting investors focused on stable revenue scaling. In the current environment of sector volatility and pipeline catalysts, this analysis highlights relative performance, growth drivers, and market positioning to aid informed trading and investment decisions.
INSM Overview and Recent Performance
Insmed Incorporated (INSM) is a global biopharmaceutical company developing therapies for serious rare diseases, primarily in respiratory conditions. Its commercial portfolio includes ARIKAYCE for nontuberculous mycobacterial lung disease and the recently launched BRINSUPRI (brensocatib) for bronchiectasis, approved in the U.S. and Europe.
In recent market activity, INSM shares have traded around $140, down approximately 20% year-to-date amid broader biotech pullbacks but up over 85% over the past year. Full-year 2025 revenue surged to $606 million, exceeding forecasts, fueled by ARIKAYCE growth and BRINSUPRI's $173 million debut, including $145 million in its first full quarter. Management guided 2026 revenue to over double 2025 levels, with BRINSUPRI at least $1 billion and ARIKAYCE $450-470 million, driving positive sentiment despite Q4 EPS misses and pipeline setbacks like the CRSsNP trial discontinuation. Trading near its 52-week midpoint ($60-$213), volatility reflects execution risks in rare disease commercialization.
LLY Overview and Recent Performance
Eli Lilly and Company (LLY) is a leading pharmaceutical firm with a diversified portfolio emphasizing diabetes, obesity, oncology, and immunology. Blockbusters Mounjaro and Zepbound (tirzepatide) drive growth in the GLP-1 market.
Recently, LLY shares hover near $985, down about 8% year-to-date and 24% over one year, underperforming amid pricing pressures and competition but up significantly longer-term. 2025 revenue hit $65 billion, a 45% rise, powered by incretin drugs; Q4 results beat estimates, prompting 2026 guidance of $80-83 billion revenue and $33.50-35 EPS. Sentiment has softened on compounded drug recalls, safety concerns, and rivals like Novo Nordisk, yet investments like $3 billion in China signal expansion. With a P/E of 43 and low beta (0.43), shares reflect premium valuation for scale versus recent monthly dips.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of top-performing AI trading bots from its library of 351 bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like AI/ML pattern recognition, technical analysis, and fundamentals, operating on timeframes from 5 minutes to 60 minutes. The 25 trending bots spotlight current market leaders, boasting annualized returns up to +209%, win rates from 52% to 95%, and profit factors reaching 4.96. Examples include semiconductor-focused bots yielding +102% with 70% wins on tickers like SOXL, and volatility plays on USAR/SMR/CIFR at +209%. Tailored for varying risk appetites, they offer real-time signals and customizable copy trading without minimum balances. Explore these high-potential tools to enhance your strategy in dynamic markets like biotech and pharma.
Head-to-Head Comparison
INSM and LLY contrast sharply in scale and focus. Insmed's niche biotech model chases explosive growth in rare pulmonary diseases via targeted launches, contrasting Lilly's diversified pharma powerhouse with mass-market GLP-1 dominance. Growth drivers diverge: INSM's revenue doubling on BRINSUPRI uptake versus LLY's 25%+ expansion from obesity volumes.
Recent momentum favors INSM's 86% 1-year gain over LLY's 24%, though both lag YTD amid sector headwinds. Risks heighten for INSM (beta 1.17, losses) versus LLY's stability (beta 0.43, profitable), with $30B vs. $880B market caps underscoring liquidity trade-offs. Sector exposure pits INSM's rare disease volatility against LLY's competitive GLP-1 arena. Sentiment tilts toward INSM on catalysts like EU launches, while LLY benefits from scale but faces pricing scrutiny.
Tickeron AI Verdict
Tickeron’s AI currently favors LLY for its superior trend consistency, lower volatility, proven profitability, and dominant positioning in high-demand GLP-1 markets with multi-billion guidance. While INSM shows stronger recent momentum and upside potential from launches, LLY's scale and catalysts suggest higher probability of relative outperformance in volatile conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a StrongBuy and LLY is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INSM’s FA Score shows that 0 FA rating(s) are green whileLLY’s FA Score has 2 green FA rating(s).
- INSM’s FA Score: 0 green, 5 red.
- LLY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INSM’s TA Score shows that 3 TA indicator(s) are bullish while LLY’s TA Score has 5 bullish TA indicator(s).
- INSM’s TA Score: 3 bullish, 7 bearish.
- LLY’s TA Score: 5 bullish, 3 bearish.
Price Growth
INSM (@Biotechnology) experienced а -5.51% price change this week, while LLY (@Pharmaceuticals: Major) price change was -1.04% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.61%. For the same industry, the average monthly price growth was +12.41%, and the average quarterly price growth was +11.94%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.06%. For the same industry, the average monthly price growth was +4.67%, and the average quarterly price growth was +7.76%.
Reported Earning Dates
INSM is expected to report earnings on Apr 30, 2026.
LLY is expected to report earnings on Apr 30, 2026.
Industries' Descriptions
@Biotechnology (+6.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+2.06% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| INSM | LLY | INSM / LLY | |
| Capitalization | 30.8B | 822B | 4% |
| EBITDA | -1.18B | 31.7B | -4% |
| Gain YTD | -17.944 | -14.260 | 126% |
| P/E Ratio | N/A | 40.08 | - |
| Revenue | 606M | 65.2B | 1% |
| Total Cash | 1.43B | 7.27B | 20% |
| Total Debt | 587M | 42.5B | 1% |
INSM | LLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 37 | 20 | |
SMR RATING 1..100 | 100 | 13 | |
PRICE GROWTH RATING 1..100 | 49 | 55 | |
P/E GROWTH RATING 1..100 | 100 | 93 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LLY's Valuation (69) in the Pharmaceuticals Major industry is in the same range as INSM (76) in the Biotechnology industry. This means that LLY’s stock grew similarly to INSM’s over the last 12 months.
LLY's Profit vs Risk Rating (20) in the Pharmaceuticals Major industry is in the same range as INSM (37) in the Biotechnology industry. This means that LLY’s stock grew similarly to INSM’s over the last 12 months.
LLY's SMR Rating (13) in the Pharmaceuticals Major industry is significantly better than the same rating for INSM (100) in the Biotechnology industry. This means that LLY’s stock grew significantly faster than INSM’s over the last 12 months.
INSM's Price Growth Rating (49) in the Biotechnology industry is in the same range as LLY (55) in the Pharmaceuticals Major industry. This means that INSM’s stock grew similarly to LLY’s over the last 12 months.
LLY's P/E Growth Rating (93) in the Pharmaceuticals Major industry is in the same range as INSM (100) in the Biotechnology industry. This means that LLY’s stock grew similarly to INSM’s over the last 12 months.
| INSM | LLY | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 74% |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 61% |
| MACD ODDS (%) | 1 day ago 70% | 1 day ago 68% |
| TrendWeek ODDS (%) | 1 day ago 72% | 1 day ago 59% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 69% |
| Advances ODDS (%) | 21 days ago 71% | 13 days ago 71% |
| Declines ODDS (%) | 6 days ago 73% | 6 days ago 55% |
| BollingerBands ODDS (%) | 1 day ago 70% | 5 days ago 81% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 59% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SUSA | 143.81 | 0.02 | +0.01% |
| iShares ESG Optimized MSCI USA ETF | |||
| HPS | 14.64 | N/A | N/A |
| John Hancock Preferred Income Fund III | |||
| LJUL | 23.98 | N/A | N/A |
| Innovator Premium Income 15 Buf ETF -Jul | |||
| HISF | 44.95 | -0.01 | -0.03% |
| First Trust High Income Strat Foc ETF | |||
| BITU | 14.57 | -0.46 | -3.06% |
| ProShares Ultra Bitcoin ETF | |||